Cellectis Shifts Focus, Drops Leukemia CAR-T Candidate to Prioritize Two Key Therapies
Biotech company Cellectis has announced a strategic shift in its CAR-T therapy pipeline, choosing to deprioritize UCART123, a leukemia-targeted candidate, ...
Biotech company Cellectis has announced a strategic shift in its CAR-T therapy pipeline, choosing to deprioritize UCART123, a leukemia-targeted candidate, ...
© 2020 The Lagos Today - Nkali.